BlackRock Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

BlackRock Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-274,820	Closed	-$322K	–	4052
2016 Q1	$322K	Buy	274,820 +4,376	+2%	+$6.79K	﹤0.01%	3059
2015 Q4	$663K	Buy	270,444 +1,417	+0.5%	+$4.06K	﹤0.01%	2865
2015 Q3	$807K	Sell	269,027 -194	-0.1%	-$837	﹤0.01%	2755
2015 Q2	$1.11M	Buy	269,221 +257,272	+2,153%	+$1.03M	﹤0.01%	2686
2015 Q1	$52K	Buy	11,949 +2,150	+22%	+$7.75K	﹤0.01%	3324
2014 Q4	$29K	Sell	9,799 -514	-5%	-$1.41K	﹤0.01%	3393
2014 Q3	$34K	Buy	10,313 +408	+4%	+$1.07K	﹤0.01%	3336
2014 Q2	$25K	Buy	+9,905	New	+$21.2K	﹤0.01%	3345

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock Investment Management's CPRX Position: Q2 2016 in Review

BlackRock Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2016, closing a stake of 274,820 shares — an estimated $322K sold.

BlackRock Investment Management first reported a position in CPRX in Q2 2014 and held it in 8 quarters. The position peaked at $1.11M in Q2 2015. 62 funds tracked by Wall St. Rank hold CPRX as of Q2 2016.

BlackRock Investment Management reported no remaining Catalyst Pharmaceutical position as of Q2 2016 after selling out during the quarter.
BlackRock Investment Management sold 274,820 Catalyst Pharmaceutical shares in Q2 2016, an estimated $322K.
BlackRock Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 8 quarters.
BlackRock Investment Management's Catalyst Pharmaceutical position peaked at $1.11M in Q2 2015.
62 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.